Special Focus Issue: BiomarkersEditorial CommentShould Enrichment With Natriuretic Peptide Levels Be Mandatory in Global Clinical Trials?∗
Editorial Comment
Under an Elsevier user license
open archive
Corresponding Author
Key Words
cardiac biomarkers
clinical trials
heart failure with reduced ejection fraction
Cited by (0)
Dr. Voor is a consultant for and has received support from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Cytokinetics, MyoKardia, Novartis, NovoNordisk, and Roche Diagnostics.
The author attests they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the JACC: Heart Failure author instructions page.
- ∗
Editorials published in JACC: Heart Failure reflect the views of the authors and do not necessarily represent the views of JACC: Heart Failure or the American College of Cardiology.
© 2020 by the American College of Cardiology Foundation. Published by Elsevier.